Literature DB >> 17604543

Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases.

Ivana Maida1, Vincent Soriano, Pablo Barreiro, Pablo Rivas, Pablo Labarga, Marina Núñez.   

Abstract

Hepatitis C virus (HCV)-infected patients with normal transaminases may show significant liver damage. The proportion of subjects with alanine aminotransferase (ALT) levels within normal limits was examined in HIV-infected patients never exposed to interferon and with detectable plasma HCV-RNA on regular follow-up at one single institution. Liver fibrosis was evaluated using transient elastography (FibroScan). Out of 281 coinfected patients, 25 (8.9%) had persistently normal ALT levels. Patients with HCV genotypes 2 (1/5; 20%) and 4 (10/50; 20%), more often had significantly normal ALT than patients with HCV-1 (13/158; 8%) (p = 0.01) and HCV-3 (1/49; 2%) (p = 0.01). Liver fibrosis stages in these patients were as follows: F0-F1 in 13 (59.1%), F2 in 4 (18.2%), F3 in 2 (9.1%), and F4 in 3 (13.6%). Advanced liver fibrosis (F3-F4) tended to be more frequent in patients infected with HCV-4 than HCV-1 (33.3% versus 9.1%; p = 0.2). Of HIV-infected patients with chronic hepatitis C 8.9% show persistently normal ALT levels. Nearly 25% of HIV-HCV-coinfected patients with persistently normal ALT show advanced liver fibrosis. Therefore, HCV-HIV-coinfected patients with normal ALT levels should be closely monitored.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17604543     DOI: 10.1089/aid.2006.0085

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

Review 1.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

2.  The impact of human T-cell lymphotropic virus I infection on clinical and immunologic outcomes in patients coinfected with HIV and hepatitis C virus.

Authors:  Fabianna Bahia; Vinicius Novais; Jennifer Evans; Chloe Le Marchand; Eduardo Netto; Kimberly Page; Carlos Brites
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08       Impact factor: 3.731

Review 3.  HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.

Authors:  Eva A Operskalski; Andrea Kovacs
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

Review 4.  Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review.

Authors:  Ashwani-K Singal; Bhupinderjit S Anand
Journal:  World J Gastroenterol       Date:  2009-08-14       Impact factor: 5.742

5.  Establishment of a standardized liver fibrosis model with different pathological stages in rats.

Authors:  Li Li; Zongqiang Hu; Wen Li; Mingdao Hu; Jianghua Ran; Peng Chen; Qiangming Sun
Journal:  Gastroenterol Res Pract       Date:  2012-06-12       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.